Bristol-Myers Squibb (BMY) has announced a transformative global collaboration and licensing deal with Jiangsu Hengrui Pharmaceuticals, valued at up to $15.2 billion. This strategic partnership targets the development of 13 early-stage programs in oncology, hematology, and immunology, addressing significant unmet medical needs. The alliance not only enhances BMY's portfolio but also underscores its commitment to innovative science in critical therapeutic areas, as the company strives to maintain strong earnings momentum amidst growing market pressures.
“Bristol-Myers Squibb · signed · collaboration and licensing agreements · to develop”
“Bristol-Myers Squibb · has entered · multi billion dollar drug development alliance · with Hengrui Pharma”
“Bristol-Myers Squibb · covers · 13 early stage oncology, hematology, and immunology programs · under a broad licensing and co development framework”
“Bristol Myers Squibb and Hengrui Pharma · have entered into · global strategic collaboration and license agreements · to advance a portfolio of 13 early stage programs in oncology, hematology and immunology”
“both companies · are focused on · advancing innovative science through partnership · in areas of significant unmet medical need”
“Bristol-Myers Squibb Company · is · one of the 10 Best Biotech Stocks to Invest In · According to Billionaire Steve Cohen”
“Bristol-Myers Squibb Company · announced · first-quarter adjusted earnings · $1.58 per share”
“Bristol-Myers Squibb Company · is involved in · the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products”
“Bristol-Myers Squibb (BMY) · Market Cap · Market Cap · $115.51B”
“Bristol-Myers Squibb (BMY) · TTM ROIC · TTM ROIC · 16.43%”
“Bristol-Myers Squibb · has signed a collaboration and licensing agreement with · Jiangsu Hengrui Pharmaceuticals · $15.2 billion”
“Bristol Myers Squibb · is · a global biopharmaceutical company”
.svg&width=160)